Iron‐dexamethasone nanoparticles mitigate acute neutrophilic inflammation
Bioengineering & Translational Medicine · 2026-11 · 11 (6)
DOI: 10.1002/btm2.70173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioengineering & Translational Medicine, online erschienen am 19.08.2026. Verfasst von Michael L Felder und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering University of Michigan Ann Arbor Michigan USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Neutrophils are the primary immune cell type present within the blood and the first to arrive at sites of inflammation. As such, neutrophils set the stage for how the inflammatory response progresses and resolves. In some cases of non‐resolving inflammation, excessive neutrophil accumulation can cause tissue damage. Accordingly, maintaining tight control over their recruitment and behavior at sites of inflammation is paramount. Historically, corticosteroids have been used to modulate inflammation, but they are associated with systemic side effects that have limited their use. Here, we developed an iron‐dexamethasone nanoparticle (DexOx NP) therapeutic that modulates neutrophil behavior and reroutes neutrophils away from sites of inflammation. DexOx NPs inhibit neutrophil activation, as indicated by prevention of L‐selectin shedding and reduced neutrophil extracellular trap formation. Furthermore, treatment with DexOx NPs in a murine acute lung injury model significantly reduced the total number of neutrophils in the bronchoalveolar lavage fluid while avoiding the side effects of systemic soluble dexamethasone phosphate delivery. Thus, DexOx NPs represent a new option to control non‐resolving neutrophilic inflammation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemical Engineering University of Michigan Ann Arbor Michigan USA.
- Department of Biomedical Engineering University of Illinois Chicago Chicago Illinois USA.
ORCID-Profile: Michael L Felder, M Valentina Guevara, Daniel Kupor, Omolola Eniola-Adefeso
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Felder, M. L., Guevara, M. V., Kupor, D., & Eniola-Adefeso, O. (2026). Iron‐dexamethasone nanoparticles mitigate acute neutrophilic inflammation. Bioengineering & Translational Medicine, 11(6). https://doi.org/10.1002/btm2.70173
Vancouver
Felder ML, Guevara MV, Kupor D, Eniola-Adefeso O. Iron‐dexamethasone nanoparticles mitigate acute neutrophilic inflammation. Bioengineering & Translational Medicine. 2026;11(6). doi:10.1002/btm2.70173
BibTeX
@article{Felder2026,
author = {Felder, Michael L and Guevara, M Valentina and Kupor, Daniel and Eniola-Adefeso, Omolola},
title = {Iron‐dexamethasone nanoparticles mitigate acute neutrophilic inflammation},
journal = {Bioengineering & Translational Medicine},
year = {2026},
volume = {11},
number = {6},
doi = {10.1002/btm2.70173}
}
EUVIMED